ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO0783

Triglyceride-Glucose Index Is Associated with Renal Dysfunction in Stage 2 CKD Patients

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical

Author

  • Araki, Makoto, Suwa Central Hospital, Chino, Nagano, Japan
Background

SGLT2i, nephroprotective agent, are known to improve hyperinsulinemia and hyperlipidemia, especially triglyceride metabolism. However, their effects on renal function have not been clearly elucidated. Triglyceride-Glucose Index (TGI) has gathered attention as a new marker of metabolic syndrome. Since it reflects both lipotoxicity and glucotoxicity, we investigated the relationship between TGI and renal function.

Methods

In this single-institutional observational study, we screened subjects whose blood (triglyceride, creatinine, and blood glucose) and body profile (abdominal circumference, height, and weight) assessment on the same day at annual health examinations between 2008 to 2018. Among these individuals, those with an estimated glomerular filtration rate (eGFR) value of 60–90 ml/min/1.73 m2, which indicates stage 2 chronic kidney disease (CKD) in the first year, were included in the study. The subjects were divided into two groups based on high and low mean TGI values during the course of the study. The changes in their renal function were compared. We evaluated both groups by time-to-event analysis in terms of a 30% eGFR decline.

Results

Of the 19,940 individuals (73,084 tests) who were assessed initially, only 8,203 individuals had health records beyond one year. Among these, we examined 6,164 patients with stage 2 CKD (mean age: 49.2 ± 11.1 years, observation period: 1,906.1 ± 1,084.3 days, mean eGFR 75.5 ± 7.8 ml/min/1.73 m2). Univariate analysis by the Lon-rank test showed that the renal function as significantly more deteriorated among individuals with a high TGI (P = 0.001). The difference remained significant after adjusting for gender, age, first-year eGFR, abdominal circumference, and follow-up systolic blood pressure using the propensity score matching method (p = 0.02).

Conclusion

In conclusion, among patients with mild renal dysfunction (stage 2 CKD), High TGI was associated with decreased renal function, and this did not change after adjusting for background factors.